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Abstract
Background: Combining a radioisotope with a dye-guided method is the best method for
identification of the sentinel lymph nodes (SNs) in breast cancer. However, some institutions are
limited to use of a dye-guided method alone. Recently, computed tomographic lymphography
(CTLG) employing a nonionic contrast medium has achieved SN identification.
Patients and methods: 218 patients with primary breast cancer and no clinical evidence of lymph
node metastasis were studied. SN identification was performed by CTLG and a dye-guided method.
The SN identification rate was analyzed for correlations with the clinicopathological findings.
Results: The SN identification rates were 96% with CTLG, 92% with the dye-guided method and
99% with both methods combined. The identification rates with CTLG and the combined method
were significantly lower in node-positive patients compared to node-negative patients, and
significantly lower with the combined method in vascular invasion-positive patients compared to
negative patients. In addition, the SN identification rate with the dye-guided method was
significantly lower in patients with a body mass index (BMI) of ≥ 25, whereas the BMI did not affect
the identification rate with CTLG or the combined method. Multiple SNs were detected in
approximately 20% of the patients.
Conclusion: Combined performance of CTLG and a dye-guided method enables identification of
SNs prior to breast cancer surgery. That SN identification is easier compared with by the dye-
guided method alone, and the identification rate is improved compared with either method alone.
The combination of methods was especially useful in obese patients. For patients with multiple SNs,
the combination has the further advantage of enabling accurate SN biopsy. CTLG may yield false-
negative findings in node-positive patients and patients with lymph vessel obstruction.
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Sentinel node biopsy (SNB) has become a standard surgi-
cal procedure for patients with early-stage breast cancer
[1,2]. The sentinel nodes (SN) can be identified by a dou-
ble-mapping procedure based on a gamma probe-guided
method and a dye-guided method using a radioisotope
(RI), or by a triple-mapping procedure that includes lym-
phoscintigraphy and is even more effective [1-3]. How-
ever, the RI method can be performed only at institutions
that are trained and licensed to use RI, and other institu-
tions must rely on dye methods alone for SN identifica-
tion [4-8] On the other hand, for obtaining images of the
lymph vessels and nodes, indirect lymphography seems to
be a more convenient than direct intralymphatic adminis-
tration of a contrast medium. Several studies of indirect
lymphography were reported in the 1980s [9-12], and
Suga et al., reported successfully identifying SN by three-
dimensional computed tomographic lymphography
(CTLG) using a nonionic contrast medium [6.7]. We have
also been identifying SN in breast cancer patients by CTLG
and a dye-guided method since February 2003 as a clinical
trial [5]. Here, we report our findings to date regarding the
clinical efficacy and problems associated with SN identifi-
cation by the combination of CTLG and a dye-guided
method.
Patients and methods
All studies in this paper were approved by the ethics com-
mittee of National Higashi-Tokushima Hospital. After
presenting a detailed explanation of this clinical trial,
written informed consent was obtained from all patients.
Patients
During the period from February 2003 through March
2007, 218 Japanese patients with T1N0M0 or T2N0M0
primary breast cancer were treated at the Tokushima
Breast Care Clinic. SN identification was performed by
combined application of CTLG and a dye-guided method.
In two of the patients the CTLG was performed before and
after excisional biopsy, and in one patient with bilateral
disease CTLG was performed on both sides. Thus, CTLG
was performed 221 times in total, while the dye-guided
method was performed a total of 219 times. In principle,
backup dissection was performed for patients found to be
SN metastasis-positive provided that informed consent
was granted. For metastasis-negative patients, axillary dis-
section was omitted on the basis of informed consent.
Methods
CTLG was performed as previously described [5]. Briefly,
the CT apparatus was a high-speed FX/I single-detector
helical CT scanner (GE Yokogawa Medical Systems,
Tokyo, Japan). One mL of iopamidol (Iopamiron 300;
300 mgI/ml, Schering, Osaka, Japan) was injected subcu-
taneously to the areola or both subcutaneously to the are-
ola and subcutaneously directly above the tumor, and the
SN was attempted to be identified by CT performed 1 min
later. In the case that the enhancement of the lymph ves-
sels and lymph nodes was poor, the site(s) where the con-
trast medium had been injected was massaged, and after
3–5 min the CT was repeated. SNs were predicted from CT
images by identification of enhanced lymph vessels and/
or lymph nodes and assessment of the CT values. The CT
values of lymph nodes were measured at their maximally
enhanced point. If an SN(s) was identified, a mark was
made on the skin immediately above the SN. The dye-
guided method was also performed as previously
described [5]. Briefly, 2~3 mL of indigo carmine blue was
injected subcutaneously to the areola, followed by mas-
sage of the injection site for a few minutes. Just before per-
forming an operation, we used ultrasonography to
confirm the location of SN(s) that had been identified by
CTLG. Five to 15 min later a skin incision was made at the
site(s) that were marked in the CTLG, and any blue-
stained lymph vessels and lymph nodes were identified. If
no SN(s) was identified by either the dye-guided method
or CTLG, axillary lymph node dissection was performed.
Definition of SNs
CTLG: A lymph node was defined as an SN if visual
inspection or the CT value (the increase of Hounsfield
units after subcutaneous injection) confirmed it to be
enhanced or if it was confirmed to connect to an
enhanced lymph vessel.
Dye-guided method: A lymph node was defined as an SN if
it was dyed blue or if it was confirmed to connect to a blue
lymph vessel.
SN identification rates and the clinicopathological findings
The results were analyzed in relation to the success/failure
of SN identification and various clinicopathological
parameters, including the patient age, menopausal status,
body mass index (BMI), tumor diameter, presence/
absence of excisional biopsy, histological type, presence/
absence of lymph node metastasis and presence/absence
of vascular invasion.
Statistical analysis
The relationships between the success/failure of SN iden-
tification and the clinicopathological findings were ana-
lyzed for statistical significance using the chi-square test. A
p value of <0.05 was considered to indicate statistical sig-
nificance.
Results
SN identification rates by CTLG and the dye-guided 
method
Identification of the SN(s) was achieved in 212 (96%) of
the total 221 performances of CTLG. The number ofPage 2 of 6
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With the dye-guided method the identification rate was
92% (202/219 tests). The combined identification rate
was 99% (Table 1). With CTLG, both the lymph vessels
and lymph nodes were clearly enhanced and the SNs
could be identified in 189 patients (86%). In 5 patients
(2%) the lymph vessels were not enhanced but the lymph
nodes were, and the SNs could be identified. In 7 other
patients (3%), the lymph vessels were enhanced while the
lymph nodes were not clearly enhanced, but the SNs
could be identified from the CT value. In 5 patients (2%)
neither the lymph vessels nor the lymph nodes were
enhanced, but the SNs could be identified from the CT
value. In 6 patients (3%) the lymph vessels were enhanced
but the lymph nodes were not, but the SNs could be iden-
tified on the basis of confirmation of their connection to
the enhanced lymph vessels. Finally, in 9 patients (4%)
neither the lymph vessels nor the lymph nodes were
enhanced, and SNs could not be demonstrated (Table 2).
SN identification rates and the clinicopathological findings
Analysis of the relationships between the SN identifica-
tion rates and the clinicopathological findings showed
that the SN identification rates with CTLG, the dye-guided
method and the combined method showed no differences
as a function of the age, menopausal status, tumor diam-
eter or histopathological type. However, with the dye-
guided method the SN identification rate was significantly
lower in patients with a BMI of 25 or higher, whereas with
CTLG and the combined method the SN identification
rate was not influenced by the BMI. With CTLG and the
combined method, the SN identification rate was signifi-
cantly lower in the node-positive patients, and with the
combined method it was significantly lower in patients
with vascular invasion. In addition, in the patients who
had undergone lateral-upper region excisional biopsy the
SN identification rate with CTLG was lower than in the
patients who had undergone excisional biopsy in a region
other than the lateral-upper region, although the differ-
ence did not reach statistical significance. Moreover, with
the dye-guided method the SN identification rate was
lower in the patients who had undergone excisional
biopsy, regardless of the region, compared with the
patients who had not undergone excisional biopsy (Table
3).
Size of the metastasis and the SN identification rate in 
node-positive patients
The patients found to be positive for metastasis were clas-
sified and analyzed on the basis of the size of the metasta-
sis: <0.2 mm, 0.2~2 mm and >2 mm. The results showed
that the SN identification rate by both CTLG and the dye-
guided method decreased as the size of the metastasis
increased, although the difference did not reach statistical
significance (Table 4).
Number of lymph vessels leading to SNs and the number of 
SNs
In this study, we were able to analyze the data on the
lymph vessels leading to SNs and the number of SNs of
200 patients. A single route with a single SN was the most
common pattern, seen in 68% of the patients. Multiple
routes with a single SN were detected in 4% of the
patients, while a single route with multiple SNs was seen
in 10% and multiple routes with multiple SNs were seen
in 8%. Overall, multiple SNs were identified in 18% of the
patients (Table 5).
Discussion
In breast cancer surgery, dissection of the axillary lymph
nodes is considered effective for the objectives of perform-
ing staging and achieving local control [1,13]. Therefore,
in recent years SNB has become a standard procedure for
patients with no metastasis of the axillary lymph nodes
since it avoids unnecessary dissection [1,2]. Combined
use of an RI (gamma probe-guided method and lympho-
scintigraphy) and a dye is currently considered to be more
efficient for identification of the SN(s) than single use of
either of these methods [1-3]. In Japan, there are many
institutions that do not have the necessary facilities for
using RIs and thus must use the dye-guided method alone
to identify SNs [4,5]. On the other hand, Suga et al. pro-
posed using a method called CTLG, which employs a non-
ionic contrast medium [6,7], and we have applied that
method for SN identification since February 2003 [5]. In
this paper we have reported our findings regarding the
usefulness and problems associated with combined appli-
cation of CTLG and the dye-guided method for SN identi-
fication.
Table 1: Identification rates of lymph vessels and sentinel lymph 
nodes
Dye CTLG Combination
Lymph vessels 212 (97%) 202 (91%) 215 (98%)
Sentinel lymph node 202 (92%) 212 (96%) 216 (99%)
Dye : Dye-guided method
CTLG : CT Lymphography
Combination: Combination of CTLG and Dye
Table 2: Findings of CT lymphography n = 221
Lymph vessels Nodes
Enhanced Clearly enhanced 189 (86%)
Unenhanced Clearly enhanced 5 (2%)
Enhanced Assessment of CT values 7(3%)
Unenhanced Assessment of CT values 5(2%)
Enhanced Unenhanced 6(3%)
unenhanced unenhanced 9(4%)Page 3 of 6
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with primary breast cancer that was thought to be clini-
cally free of axillary lymph node metastasis. CTLG and the
dye-guided method were employed in an attempt to iden-
tify the SN(s) in each of the patients. The SN identification
rates were 96% with CTLG alone, 92% with the dye-
guided method alone and 99% when the findings with
the two methods were combined. Those results are good
when compared with the published data for combined
use of an RI and the dye-guided method [2,3]. In particu-
lar, our SN identification rate with the dye-guided method
is better than the rates that have been reported to date
[2,3,14]. We think that this is because the location of the
SN had already been determined by the CTLG, making it
easy to identify the lymph vessels and lymph nodes. The
breakdown of the identification by CTLG showed clear
enhancing of the lymph nodes in 88% of the patients,
while in 5% of the patients identification of the SN was
possible on the basis of the CT value in spite of the fact
that the lymph nodes were not clearly enhanced. Because
the observations were macroscopic, when the dye-guided
Table 3: Sentinel node (s) identification rate and clinicopathological findings (all cases) (Dye n = 219, CTLG n = 221, Combination n = 
219)
Dye (+)(n = 202) CTLG (+)(n = 212) Combination (+)(n = 216)
Age, years
35 6(100%) 6(100%) 6(100%)
36~50 87(90%) 92(95%) 96(98%)
51 109(94%) 114(97%) 114(98%)
Menopausal state
Pre 103(92%) 108(96%) 105(98%)
Post 99(93%) 104(95%) 111(99%)
BMI
<25 160(95%) # 164(96%) 166(98%)
25 42(84%) 48(96%) 50(100%)
Tumor size, cm
2.0 183(92%) 193(96%) 197(99%)
2.1 19(100%) 19(100%) 19(100%)
With excisionary biopsy*
In lateral-upper region 17(89%) 18(95%) 19(100%)
In other regions 46(88%) 52(100%) 52(100%)
Histological type
IIa1 71(88%) 80(99%) 80(99%)
IIa2 22(100%) 23(100%) 22(100%)
IIa3 64(96%) 63(94%) 65(97%)
IIb3 8(89%) 8(89%) 9(100%)
DCIS 13(100%) 12(92%) 13(100%)
Others 24(89%) 26(93%) 27(100%)
Nodal status
n(-) 177(93%) 189(98%) # 191(100%) #
n(+) 25(89%) 23(82%) 25(89%)
Vascular invasion
v(-) 160(91%) 172(97%) 174(99%) #
v(+) 42(95%) 40(91%) 42(95%)
BMI : Body mass index        
Dye : Dye-guided method       
CTLG : CT Lymphography        
Combination: Combination of CTLG and Dye        
#; P<0.05     
*; cases with excisional biopsy (n=71) 
Table 4: Size of the metastatic lesion in the node positive cases n 
= 28
Metastatic lesion size Dye(+) CTLG(+)
Isolated tumor cells(<0.2 mm) 2(100%) 2(100%)
Micrometastasis(0.2~2 mm) 10(91%) 9(82%)
Macrometastasis(2 mm) 13(87%) 12(80%)
Dye: Dye-guided method, CTLG: CT Lymphography
Table 5: Number of lymph vessels leading to Sentinel nodes and 
the number of Sentinel nodes
Single rout and Single node 151(68%)
Multi routs and single node 8(4%)
Single rout and multi nodes 23(10%)
Multi routs and multi nodes 18(8%)Page 4 of 6
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unless the lymph node was stained to a sufficient degree.
With CTLG, on the other hand, even if the enhancement
is not very striking it can be surmised that the SN identifi-
cation rate will be improved since the CT value can be
taken into consideration.
In 14 patients, the SN was identified by CTLG, but not by
the dye-guided method. The location of the SN was con-
firmed by ultrasonography just before the operation in all
of these patients. In these 14 patients, not only the SN but
also neighboring nodes were sampled at the same time.
Therefore, it seemed that the SN biopsies had been per-
formed accurately.
The sensitivity of CTLG could not be investigated in our
patient population because backup axillary dissection was
not performed for patients who were metastasis-negative
in the SNB. In addition, none of the patients experienced
postoperative recurrence in the axillary lymph nodes, but
that does not serve as a basis for claiming that there were
few false-negatives [1]. However, Tangoku et al., reported
the sensitivity of CTLG to be 98%, and for that reason it
can be thought that the sensitivity of CTLG is not inferior
to that of the RI method [15].
With regard to correlations between the clinicopathologi-
cal findings and the SN identification rate, the patient age,
the location of the tumor, whether or not surgical biopsy
was performed, the tumor size and the presence/absence
of lymph node metastasis have been reported to influence
identification of the SN [1,16-18]. In our patient series,
the results showed no differences as a function of the age,
menopausal status, tumor diameter or histopathological
type. However, with the dye-guided method the SN iden-
tification rate was significantly lower in patients with a
BMI of 25 or higher, whereas with CTLG and the com-
bined method the SN identification rate was not influ-
enced by the BMI. As the reason for this difference it is
noted that with the dye-guided method it can be difficult
to discern staining of lymph vessels and nodes with the
naked eye if considerable subcutaneous fat is present,
whereas with CTLG the subcutaneous fat plays no role
since the observation is done by CT. In addition to the
BMI, discrepancies between the SN identification rates
with these three methods were observed as a function of
the presence/absence of lymph node metastasis, the site of
excisional biopsy (i.e., the lateral upper region and
regions other than the lateral upper region), and the pres-
ence/absence of vascular invasion. Especially, the identifi-
cation rates with CTLG and the combined method were
significantly lower in node-positive patients compared to
node-negative patients, and significantly lower with the
combined method in vascular invasion-positive patients
compared to negative patients. The size of injected parti-
cles, the injected volume and the injection site have been
reported as examination factors that can influence SN
identification [2]. The nonionic contrast media that are
used in CTLG have a larger particle size than dyes [19]. For
that reason it can be hypothesized that, in patients with
lymph node metastasis or vascular invasion and in
patients who had undergone lateral upper region exci-
sional biopsy, who can be predicted to have lymph vessel
occlusion, the movement of a nonionic contrast medium
would be impeded compared with that of a dye, thus
resulting in a lower SN identification rate. On the other
hand, the SN identification rate with the dye-guided
method was lower in the patients with excisional biopsy
in any region than in patients without excisional biopsy.
It can be hypothesized that this is probably because exci-
sional biopsy leads to edema of the connective tissue,
which makes it difficult to distinguish the dye.
We also investigated the number of SNs and the number
of lymph vessels leading to them [20-22]. These evalua-
tions are difficult to achieve by the gamma probe-guided
method and the dye-guided method, but CTLG permits
detailed investigation. Our results showed that there was
a single route leading to a single SN in 68% of the
patients, multiple routes leading to a single SN in 4%, a
single route leading to multiple SNs in 10% and multiple
routes leading to multiple SNs in 8%. These results are in
agreement with those reported by Tangoku et al., [23].
Thus, approximately 18% of the patients in our series had
multiple SNs, and it can be hypothesized that it would be
difficult to biopsy all of them if only the dye-guided
method were employed. We think that combined use of
CTLG with the dye-guided method would permit accurate
biopsy, and for that reason we anticipate that combined
performance of CTLG will prove useful.
CTLG is a diagnostic test that is performed prior to surgery
for breast cancer. Studies are warranted to determine
whether the CT findings or performance of fine-needle
aspiration cytology of the SN will make it possible to
achieve diagnosis of SN metastasis preoperatively and
then decide whether or not SNB should be performed
[24]. Such diagnosis leading to avoidance of unnecessary
surgical procedures would represent a great clinical advan-
tage by reducing the burden on the patient. Moreover, in
the future it will be necessary to compare the usefulness of
CTLG with the RI method.
Conclusion
Combined performance of CTLG with the dye-guided
method permits better elucidation of the location of the
SN(s) in breast cancer. This makes it easier to identify the
SN(s) and results in a higher SN identification rate com-
pared with application of the dye-guided method alone.
Combination of CTLG and the dye-guided method wasPage 5 of 6
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especially useful in obese patients. In addition, in patients
with multiple SNs, it is advantageous to be able to per-
form SNB accurately. However, in patients with occlusion
of the lymph vessels due to lymph node metastasis, hav-
ing undergone lateral upper region lumpectomy or the
presence of vascular invasion, there is a possibility that
false-negative diagnostic results will be generated with
CTLG.
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computed tomographic lymphography; BMI: body mass
index; RI: radioisotope.
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